iBio (IBIO) SEC Filings: History & Chart

iBio, Inc.(IBIO)

Biotechnology · San Diego, CA

$1.05-0.07 (-6.25%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About iBio, Inc.

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

San Diego, CA

23 employees

www.ibioinc.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martin Brenner

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 14, 2026	Sep 14, 2026	View filing
ARS	Sep 4, 2026	Sep 4, 2026	View filing
DEF 14A	Sep 4, 2026	Sep 4, 2026	View filing
10-K	Aug 28, 2026	Aug 28, 2026	View filing
8-K	Aug 28, 2026	Aug 28, 2026	View filing
PRE 14A	Aug 20, 2026	Aug 20, 2026	View filing
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
3	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Jul 17, 2026	Jul 17, 2026	View filing
8-K	Jul 1, 2026	Jul 1, 2026	View filing
4	May 19, 2026	May 19, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
SC 13G	May 15, 2026	May 15, 2026	View filing
3	May 15, 2026	May 15, 2026	View filing
SC 13G/A	May 14, 2026	May 14, 2026	View filing
SC 13G/A	May 12, 2026	May 12, 2026	View filing
10-Q	May 12, 2026	May 12, 2026	View filing
8-K	May 12, 2026	May 12, 2026	View filing
8-K	May 8, 2026	May 8, 2026	View filing
424B3	Apr 29, 2026	Apr 29, 2026	View filing
8-K/A	Apr 17, 2026	Apr 17, 2026	View filing
8-K	Apr 8, 2026	Apr 8, 2026	View filing

SEC Filings

Recent Filings